Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Chair criticizes Trump administration and Health Secretary Robert Kennedy over secret drug deals and Medicaid cuts
Loading...
Summary
A committee chair opened a hearing with sharp criticism of the Trump administration's health care blueprint and Health Secretary Robert Kennedy, alleging secret pharmaceutical and insurance deals, claiming widespread Medicaid-related closures and job losses, and entering multiple documents into the record.
The chair opened the hearing with a sustained critique of what he called "Donald Trump's health care blueprint for the coming year," saying the administration had struck secret deals with drug and insurance companies and was "throwing consumer protections in the trash." The chair identified himself in the remarks as the hearing's chair and asked that several documents be entered into the record.
Why it matters: The chair tied those alleged deals and policy choices to concrete harm, saying they have forced health providers to close and workers to lose jobs in multiple states and arguing that the public will not see the promised reductions in drug prices until greater transparency is provided.
The chair accused Health Secretary Robert Kennedy of using his office to promote anti-vaccine views and of repeatedly misleading Congress. "He's repeatedly lied before the congress," the chair said. He also accused the administration of hosting pharmaceutical executives in the Oval Office and negotiating secret arrangements; "The details, the important facts about these deals are totally secret," he said.
On the scale of impact, the chair said his office had cataloged "over a 170 closures and service reductions across 34 states" and that "nearly 7,500 health care workers have lost their jobs across 24 states," which he described as evidence that Republican Medicaid cuts have already impaired access to care. He asked to enter his office's analysis and submissions from five states and national news coverage into the hearing record; the clerk responded, "Without objection," each time.
The chair also challenged the administration's consumer-facing drug proposal, saying the program touted as lowering drug prices, which he called "Trump RX," "actually offers higher prices for drugs than what most people can get through their insurance." He characterized that outcome as "no bigger fraud on the planet when it comes to drug costs than Donald Trump."
Many of the claims presented were framed by the chair as findings of his staff's review or as allegations; the statements, including the counts of closures and layoffs and the claim of "secret" billion-dollar-plus deals, were presented to the committee as the chair's office's analysis and were not verified within the hearing record during these remarks.
The chair closed by saying Democrats on his side were "leading an effort to reimagine health care for American families" and that, if the secretary were serious about improving health outcomes, he would work cooperatively. "I look forward to the questions," he said.
